Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Strong Financial Health

Analyst Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics and keeping the price target at $40.00.

Gil Blum has given his Buy rating due to a combination of factors that highlight Cartesian Therapeutics’ promising future. The company has commenced enrollment for a pivotal study in severe myasthenia gravis, with results anticipated before mid-2027. This development is supported by encouraging Phase II results, which demonstrated a sustained clinical benefit over a year-long follow-up period.
Furthermore, Cartesian’s financial health appears robust, with a reported end-of-quarter cash balance of $162 million and a positive earnings per share adjustment. The upcoming Phase II data for systemic lupus erythematosus (SLE) and the initiation of a pediatric autoimmune disease study further bolster confidence in the company’s clinical pipeline. These elements collectively underpin the Buy rating, reflecting optimism about Cartesian’s strategic direction and potential for growth.